Sagimet Biosciences(US:SGMT) Newsfilterยท2025-04-23 12:00Core Viewpoint - Sagimet Biosciences Inc. is advancing its clinical-stage drug denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), with new data presentations scheduled at the EASL Congress 2025 [1][6]. Group 1: EASL Presentation Details - Three poster presentations will feature analyses from the Phase 2b FASCINATE-2 study of denifanstat, focusing on its efficacy in treating MASH [1]. - The first presentation will assess the MASH Resolution Index (MR-I) as a non-invasive biomarker for predicting histological response to denifanstat, indicating its potential to identify non-responders [2]. - The second presentation highlights the correlation between reduced plasma glycine- and taurine-conjugated bile acids and histological improvements in MASH patients treated with denifanstat [3]. - The third presentation discusses denifanstat's antifibrotic effects on collagen features linked to major adverse liver outcomes in high-risk patients [4]. Group 2: Company Overview - Sagimet is focused on developing fatty acid synthase (FASN) inhibitors, with denifanstat being its lead candidate, designed for once-daily oral administration [5]. - Denifanstat has received Breakthrough Therapy designation from the FDA for treating non-cirrhotic MASH with moderate to advanced liver fibrosis [6]. - The global prevalence of MASH is significant, affecting over 115 million people, with limited treatment options currently available [7].